Meriem N Mrabent1, Noria Harir1, Feriel Sellam1*, Soumia Zeggai1, Abdenacer Tou2, Mustapha Diaf1, Rachida Salah1 and Soraya Moulesshoul1
1Laboratory of Molecular Microbiology, Proteomics and Health, Departement of Biology, Djillali Liabes University of Sidi bel Abbes, Algeria
2Department of Pathology; Hospital of Sidi bel Abbes, Algeria
Received: 12 September, 2015; Accepted: 26 October, 2015; Published: 28 October, 2015
Feriel Sellam, PhD, Department of Biology, Djillali Liabes University of Sidi bel Abbes, (Ex ITMA), Algeria candidate in Cellular Biology and Pathology, E-mail:
Mrabent MN, Harir N, Sellam F, Zeggai S, Tou A, et al. (2015) HER2 Status in Male Breast Carcinoma: a Single North African Institution Experience of 10 Cases and Review of the Literature. J Surg Surgical Res 1(3): 049-052. 10.17352/2455-2968.000013
© 2015 Mrabent MN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Breast cancer; Man; Overexpression; ER; PR; HER2
Background: To investigate clinic-pathological characteristics, hormonal receptors and HER2 receptor of male breast cancer.
Materials and methods: Retrospective study of 10 cases between 2010 and 2013. The studied parameters were: tumor size, histological type, histological grade, lymph node status, hormonal status and overexpression of HER2.
Results: The average age of our patients was 60.2 years, in 70% of cases; the histological size that was found was T4; and infiltrating ductal carcinoma was diagnosed in all cases. The grades classification was as follow: grade 2 (30%) and grade 3 (70%). 70% of cases had lymph node metastasis. Estrogen and progesterone receptors (ER,PR) were positive in 60% of tumors. Overexpression of HER2 was positive (Score3) in one case. Luminal B was the most common subtype in our study.
Conclusion: Male breast cancer is a rare disease with a poor prognosis despite the recent increase in incidence in recent years. The diagnosis is often delayed and injuries are treated in advanced stages.
Breast cancer in men is a rare disease and makes up approximately 1% of all cases of breast cancer [1,2]. The rarity of this entity precludes prospective randomized trials. During 2014 in the USA, about 2,360 new cases of invasive breast cancer were diagnosed in men and about 430 men died from the disease . The etiology of male breast cancer is unclear, but hormone levels and testicular abnormalities play a role in the development of this disease [4,5]. Other recognized risk factors include radiation exposure, family history of breast cancer, Klinefelter syndrome, and different benign breast conditions [4,5].
Previous reports have suggested that cancers of the male breast are more likely than female breast cancers to have a ductal histology and are significantly more likely to express hormone receptors [6,7]. Early reports suggested equivalent or even higher rates of human epidermal growth factor receptor 2 (HER2) overexpression in male breast cancer versus female breast cancer [8,9]. Overexpression of the oncoprotein HER2 observed in 10-15% of patients could justify prescribing trastuzumab. In the context of the considerable progress achieved in the recent years concerning female’s breast cancer management, it seems important to review the acquired data and to exploit these advances in order to improve male breast cancer care . In this study we will explore the following pathological parameters: histological type, tumor size, histological grade, lymph node status, hormonal and HER2 status of male breast cancer from western Algeria and compared them with different literatures data.
Material and Method
This cross sectional study was done at the department of pathology at Sidi Bel Abbes University Hospital in Western Algeria from 2010 to 2013. The Male patients with breast cancer were selected for the study. The cases were stained with hematoxyline and eosin (H&E) for routine histological examination. An absolute confidentiality of the patients’ vital information was maintained for ethical purposes and an ethical approval was obtained from institutions in which the study was carried out. We used immunohistochemistry to evaluate the expression of HER2, ER, and PR receptor.
Immunohistochemical expression of HER2 was evaluated according to the published scoring guidelines of the ‘HercepTest’ (Dako, Carpinteria, CA). Herceptest of score 3+ was considered as positive. Four subtypes were defined: 1) Luminal A; oestrogen receptor (ER) + and/or progesterone receptor (PR) +, HER2 -, grade 1 or grade 2 tumours, 2) Luminal B; ER + and/or PR + and HER2 + tumours or ER+ and /or PR+ and HER2- grade 3 tumours, 3) HER2+; ER -, PR- and HER2 + tumours, 4) Triple negative; ER-, PR-,HER2- tumours.
Graph and circles were done using the SPSS Inc. software (Version20).
10 patients with breast cancer were included; and all of them were men. Median age was about 60.2 years (range, 42-80); The most affected age groups were 52-61 years (40%) followed by 62 -71 age group (30%) (Figure 1).
- Giordano SH, Cohen DS, Buzdar AU, Perkins G, Hortobagyi GN (2004) Breast carcinoma in men: a population-based study. Cancer 101: 51-57 .
- Burstein HJ, Harris JR, Morrow M (2011) Malignant tumors of the breast. In: DeVita VT Jr, Lawrence TS, Rosenberg SA: Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins 1401-1446.
- American Cancer Society. Cancer Facts and Figures (2014). Atlanta, GA: American Cancer Society .
- Giordano SH, Buzdar AU, Hortobagyi GN (2002) Breast cancer in men. Ann Intern Med 137: 678-687 .
- Korde LA1, Zujewski JA, Kamin L, Giordano S, Domchek S, et al. (2010) Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 28: 2114-2122 .
- Anderson WF, Althuis MD, Brinton LA, Devesa SS (2004) Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat 83: 77-86 .
- Stalsberg H, Thomas DB, Rosenblatt KA, et al. (1993) Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control 4: 143-151 .
- Leach IH, Ellis IO, Elston CW (1992) c-erb-B-2 expression in male breast carcinoma. J Clin Pathol 45: 942 .
- Gattuso P, Reddy VB, Green LK, Castelli MJ, Wick RM (1995) Prognostic factors for carcinoma of the male breast. Int J Surg Pathol 2: 199-206 .
- Comet B, Cutuli B, Penault-Llorca F, Bonneterre J, Belkacémi Y (2009) Male breast cancer: a review. Bull Cancer 96: 181-189 .
- Anderson WF, Jatoi I, Tse J, Rosenberg PS (2010) Male breast cancer: a population-based comparison with female breast cancer. J Clin Onc 28: 232-239 .
- Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ (1999) An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 126: 775–780.
- Cutuli B, Lacroze M, Dilhuydy JM, Velten M, De Lafontan B, et al. (1995) Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31A 1960-1964 .
- Stierer M, Rosen H, Weitensfelder W, Hausmaninger H, Teleky B, et al. (1995) Male breast cancer: Austrian experience. World J Surg 19: 687-692 .
- Lartigau E, el-Jabbour JN, Dubray B, Dische S (1994) Male breast carcinoma: a single centre report of clinical parameters. Clin Oncol (R Coll Radiol 6: 162-166 .
- Borgen PI, Wong GY, Vlamis V, Potter C, Hoffmann B, et al. (1992) Current management of male breast cancer. A review of 104 cases. Ann Surg 215: 451-457 .
- Dawson PJ, Paine TM, Wolman SR (1992) Immunocytochemical characterization of male breast cancer. Mod Pathol 5: 621-625.
- Wick MR, Sayadi H, Ritter JH, Hill DA, Reddy VB, et al. (1999) Low-stage carcinoma of the male breast. A histologic, immunohistochemical, and fow cytometric comparison with localized female breast carcinoma. Am J Clin Pathol 111: 59-69 .
- Bloom KJ, Govil H, Gattuso P, Reddy V, Francescatti D (2001) Status of HER-2 in male and female breast carcinoma. Am J Surg 182: 389-392.
- Blin N, Kardaś I, Welter C, Ryś J, Niezabitowski A, et al. (1993) Expression of the c-erbB2 protooncogene in male breast carcinoma: lack of prognostic signifcance. Oncology 50: 408-411 .
- Rayson D1, Erlichman C, Suman VJ, Roche PC, Wold LE, et al. (1998) Molecular markers in male breast carcinoma. Cancer 83: 1947-1955 .
- Muir D, Kanthan R, Kanthan SC (2003) Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med 127: 36-41 .
- Sánchez-Muñoz A, Román-Jobacho A, Pérez-Villa L, Sánchez-Rovira P, Miramón J, et al. (2012) Male breast cancer: immunohistochemical subtypes and clinical outcome characterization. Oncology 83: 228-233 .
- Ge Y, Sneige N, Eltorky MA, Wang Z, Lin E, et al. (2009) Immunohistochemical characterization of subtypes of male breast carcinoma. Breast Cancer Res 11: R28
- Nilsson C, Johansson I, Ahlin C, Thorstenson S, Amini RM, et al. (2013) Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol 52: 102-109 .
- Deb S, Jene N, Kconfab Investigators, Fox SB (2012) Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer 12: 510 .
- Johansson I, Nilsson C, Berglund P, Lauss M, Ringnér M, et al. (2012) Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res 14: R31 .
- Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, et al. (2012) Immunophenotyping of male breast cancer. Histopathology 61: 1145-1155 .
- Ruddy KJ, Winer EP (2013) Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol 24:1434-1443 .